RxDoctor Payments Data

Megan Esch, MD

Neurology · Danville, PANPI 1982041315

Payments from drug & device makers

$88,531in general payments, 2019–2025

Across 51 payments — averaging $1735.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$80K
  • AstraZeneca$5K
  • Novartis$3K
  • TG Therapeutics, Inc.$675
  • E.r. Squibb & Sons, L.L.C.$30

What the payments were for

  • Consulting fees$13,38919%
  • Speaking & faculty fees$55,69880%
  • Food & beverage$6751%
  • Education$300%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen43$79,912
AstraZeneca1$5,120
Novartis4$2,795
TG Therapeutics, Inc.1$675
E.r. Squibb & Sons, L.L.C.2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,531 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$21,629
Medicare patients
155
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab39$365,307
TecfideraDimethyl Fumarate17$152,610
AubagioTeriflunomide12$111,364
ZeposiaOzanimod Hydrochloride12$110,926
Plegridy PenPeginterferon Beta-1a11$100,430
GlatopaGlatiramer Acetate12$54,441
Glatiramer Acetate21$38,021
Dimethyl Fumarate16$32,304
Aimovig AutoinjectorErenumab-Aooe11$7,959
Dalfampridine ErDalfampridine54$6,805
Baclofen66$2,116
Pregabalin22$1,238
Gabapentin29$1,136
Carbidopa-LevodopaCarbidopa/Levodopa23$811
Levetiracetam11$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$79,912$152,61017 claims
E.r. Squibb & Sons, L.L.C.Zeposia$30$110,92612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Danville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →